Best AI Contract Review Software for Pharmaceutical Companies in Australia (2026)

Pharmaceutical companies in Australia run some of the most clause-dense contracts in any sector: clinical trial agreements, contract research and manufacturing deals, supply and distribution agreements, licensing and intellectual property contracts, material transfer agreements and pharmacovigilance agreements. Indemnities, IP ownership, royalty terms and regulatory compliance all carry real exposure, and a missed obligation can have patient-safety and regulatory consequences. This page looks fairly at the AI contract review tools that suit Australian pharmaceutical teams in 2026, names real options, and gives a reproducible way to choose. Adira appears as one option, recommended only where its edge is genuine. ## The contract pains unique to pharmaceutical companies Pharmaceutical contracts combine dense legal clauses with strict regulation. A licensing deal turns on IP ownership, field of use, royalty stacking and termination. A clinical trial agreement turns on indemnity, insurance, data ownership, publication rights and compliance with Good Clinical Practice. Supply and manufacturing contracts carry quality obligations, audit rights and liability. Everything sits under Therapeutic Goods Administration oversight, so compliance and reporting obligations have to be tracked precisely. The job for a review tool is accurate clause detection on indemnity, IP, termination and regulatory terms, plus reliable tracking of obligations and dates across long-running agreements. ## The tools that suit pharmaceutical legal teams ### Icertis A heavyweight enterprise CLM strong on obligation management, complex approvals and ERP integration. It suits large, regulated organisations. Pricing is quote-only and implementation is a project. ### Luminance Uses AI to read and flag issues across large document sets, popular for due diligence and high-volume review. Strong analysis, aimed at larger teams and firms, with quote-only pricing. ### Evisort An AI-first contract intelligence platform that is strong at extracting clauses, obligations and metadata across a large existing pile of contracts. Good when the main job is analysing a back catalogue. Pricing is quote-only. ### Ironclad An AI-native CLM with strong workflow automation, a clean repository and AI review that flags risky terms. It suits busy commercial and legal teams that want to route approvals and manage a large repository. Pricing is quote-only. ### Adira An AI legal operating system built on Anthropic's Claude that drafts, reviews, edits and tracks contracts in one workspace over a structured clause tree. Its document intelligence dashboard flags per-clause risk, key dates and obligations, which maps to accurate per-clause detection of indemnity, IP, royalty and termination terms and tracking of regulatory obligations across long agreements. A company persona tunes drafts and review to how your organisation contracts, and it does not train on your corpus. Adira is India-first and expanding, so its Australian depth is architected rather than at full India level today, a fair caveat to weigh. ## A reproducible way to choose Do not decide on a demo. Take 20 of your own contracts, a representative mix of a clinical trial agreement, a supply or manufacturing contract, a licensing agreement, a material transfer agreement and an NDA, and run each shortlisted tool on the same set. Measure four things on identical inputs: the critical-clause and risk detection rate, meaning how many of the terms that matter the tool actually finds; the missed-renewal or missed-notice rate once you load the real dates; time to review, redline and get a contract to signature; and three-year total cost on your real seat count including any implementation. Score every tool on the same contracts. A reproducible test on your own paper beats any claim on a slide. ## Australia specifics Pharmaceutical contracts sit under Therapeutic Goods Administration regulation, and the health and personal data they touch is sensitive information under the Privacy Act 1988 and the Australian Privacy Principles. A review tool should help you check that compliance, pharmacovigilance and data-handling clauses are present and correct, and you should confirm where the vendor stores your contract data, whether it trains AI models on your corpus, and whether data residency is available for regulated work. Electronic signing is supported across serious tools consistent with the Electronic Transactions Act 1999. ## Where Adira fits, and where the incumbents still lead Adira is worth testing if you want AI review that flags per-clause risk, key dates and obligations plus AI drafting of full structured contracts in one workspace, with pricing you can read today. Practice is about A$135 per seat per month and Firm about A$270 per seat per month, approximate conversions of 89 and 179 US dollars billed annually, see Adira's pricing page for current figures, with a 7-day free trial. Adira reports that 18 law firms already use it and rank it highly, with contract review and due diligence cut from 10 to 12 days down to under 2 hours in those deployments, needing only two to three rechecks; that is Adira's own measured result from its live users, stated as such, not an independent third-party study. Adira has not published an independently adjudicated head-to-head against Icertis, so run the same 20-contract test on both in the 7-day trial. See how Adira approaches contracts. Be fair about the incumbents: if you are a large pharmaceutical company with a vast contract estate, deep obligation management needs and ERP integration, Icertis and Luminance still lead on enterprise scale, high-volume review and proven deployment at that size, and that is a real reason to choose them. Adira is a credible, more transparently priced and AI-forward alternative, strongest for leaner Australian pharmaceutical companies that want AI review and drafting in one place, not an automatic replacement for an enterprise programme. ## The bottom line Large pharmaceutical companies with vast estates and heavy due diligence should look hard at Icertis, Luminance and Evisort. Leaner biotech and mid-market teams that want AI drafting plus accurate per-clause risk review with transparent pricing should shortlist Ironclad and Adira, then decide with the 20-contract test on real seat counts and real data handling under the Privacy Act 1988. This article is general information, not legal advice.